Title
Comparative evaluation of core temperature measurement and invasive temperature monitoring in an intensive care setting ICU-TEMP

Rationale
Fever is one of the most common clinical symptoms. So far, clinically established methods to monitor core body temperature (CBT) are either invasive and expensive (blood, bladder or rectal catheter) and/or non-continuous (tympanic temperature measurements). A continuous and scalable CBT monitoring solution is missing. The Corsano CardioWatch 287-2 is a wristband intended to monitor multiple vital signs, including CBT. It does so by continuously measuring the wrist’s skin temperature and corresponding heat flux, from which it predicts the CBT. These CBT predictions are performed in real-time by a machine learning algorithm on the wearable itself.

Primary End-Point
The main objective is to validate the clinical accuracy of CBT spot measurements by the Corsano CardioWatch 287-2 according to ISO 80601-2-56;2017+A1;2018.

Secondary End-Point
The secondary end-point is to compare continuous CBT measurements by the Corsano CardioWatch 287-2 with measurements from a clinically conventional, continuous rectal temperature sensor.

Study Design
This is a single-center study. Temperature readings from wearable CBT sensors, tympanic temperature and rectal temperature will be collected. Each participant will remain in the study for a minimum of 3 hours and up to 6 days. Other than the wearable CBT sensor, no additional interventions will take place due to the study. Temperature monitoring of patients will be performed according to hospitals routine care and will not be affected by the study.

Study population
We aim to include 105 individuals (mixed gender), of which 30-50% are displaying fever (>38°C), who are administered to the intensive care unit of the Reinier de Graaf Gasthuis.

Inclusion / Exclusion criteria
Inclusion Patients:
● ≥ 18 years old;
● able to provide consent.
● receiving rectal temperature monitoring as standard of care in the ICU of the Reinier de Graaf hospital.

Exclusion:
● Unable to wear the Corsano CardioWatch 287 due to reasons such as allergic reactions, wounds, amputations etc.;
● Unable to receive rectal temperature monitoring;
● Active external heating or active external cooling of the patient (targeted temperature management system);
● Thermoregulatory problems or diseases;
● Sepsis / cold fever;
● Hyperthermia;
● Known allergy to plastics / latex;
● Pregnant women;
● Breastfeeding women;
● Unable or not willing to sign informed consent;
● Significant mental or cognitive impairment.

Study center
Reinier de Graaf Gasthuis Delft (NL)

Start time, Duration
July 2024, 3 months

Interested in our Trial Programme?

Corsano Cardiowatch Bracelets enable continuous monitoring with multiple algorithms. Corsano is working closely with cardiologists, scientists, hospitals, patients, and research organisations.  Scientific research demonstrates the legitimacy of Cardiowatch 287 algorithms. 

We are currently performing pilots with selected clients. Contact us if you want to know more!

Corsano CardioWatch is a wrist worn medical grade multi sensor bracelet to capture up to 19 vital parameters. Primary use cases are 24/7 continuous clinical trials and remote patient monitoring.  
 
The bracelet monitor offers flexibility to set data collection intervals by minute, by second or 25Hz, 32 Hz or 128 Hz. We measure Heart Rate, RR intervals, Breathing Rate, A-Fib detection, Skin Temperature, Activity and Sleep. SpO2, Core Body Temperature, ECG and Blood Pressure are in development.  
 
Clinical accuracy is paramount for us. In addition to third parties' algorithms, i.e. from Philips, we run our proprietary algorithms to realize superior data accuracy. Corsano technology has been clinically validated in major academic hospitals. The bracelet is manufactured under ISO 13485 and CE-MDR compliance. The process for FDA Clearance has started. 
 
Our end-to-end solution consists of light-weight and comfortable bracelets with a patient research portal. We have developed and produced over 200’000 devices. The Corsano platform has been optimized on connections, data buffers and battery life up to 15 days. We offer access to raw continuous high frequency data through API and cloud-to-cloud solutions. 
 

The founders of Corsano Health have over 100 years of experience in the Swiss Watch industry, with deep experience about ergonomic design and materials for wearables that are worn 24/7.